These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

543 related articles for article (PubMed ID: 26575171)

  • 1. Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?
    Niyazi M; Harter PN; Hattingen E; Rottler M; von Baumgarten L; Proescholdt M; Belka C; Lauber K; Mittelbronn M
    Oncotarget; 2016 Jan; 7(3):2313-28. PubMed ID: 26575171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
    Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
    Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
    Winkler F; Osswald M; Wick W
    Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
    Miletic H; Niclou SP; Johansson M; Bjerkvig R
    Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis inhibitors in tackling recurrent glioblastoma.
    Hundsberger T; Reardon DA; Wen PY
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in high-grade gliomas: past, present, and future.
    Curry RC; Dahiya S; Alva Venur V; Raizer JJ; Ahluwalia MS
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):387-97. PubMed ID: 25797685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme.
    Onishi M; Kurozumi K; Ichikawa T; Date I
    Neurol Med Chir (Tokyo); 2013; 53(11):755-63. PubMed ID: 24162241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
    Omar AI
    J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-angiogenic strategies in glioblastoma].
    Guillamo JS
    Rev Neurol (Paris); 2011 Oct; 167(10):662-7. PubMed ID: 21889779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
    Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y
    EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Directions in Anti-Angiogenic Therapy for Glioblastoma.
    Wang N; Jain RK; Batchelor TT
    Neurotherapeutics; 2017 Apr; 14(2):321-332. PubMed ID: 28083806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?
    Seystahl K; Weller M
    Expert Opin Investig Drugs; 2012 May; 21(5):605-17. PubMed ID: 22413865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of anti-angiogenic strategies for glioblastoma.
    Thomas AA; Omuro A
    Curr Treat Options Oncol; 2014 Dec; 15(4):551-66. PubMed ID: 25173555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of VEGF in the treatment of glioblastoma.
    Robles Irizarry L; Hambardzumyan D; Nakano I; Gladson CL; Ahluwalia MS
    Expert Opin Ther Targets; 2012 Oct; 16(10):973-84. PubMed ID: 22876981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
    Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
    Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.